Tobacco Products Scientific Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments
[Federal Register Volume 91, Number 224 (Monday, November 23, 2026)]
[Notices]
[Pages 75515-75516]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2026-23750]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2026-N-13368]
Tobacco Products Scientific Advisory Committee; Notice of
Meeting; Establishment of a Public Docket; Request for Comments
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; establishment of a public docket; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming
public advisory committee meeting of the Tobacco Products Scientific
Advisory Committee (TPSAC, the Committee). The general function of the
Committee is to provide advice and recommendations to FDA on regulatory
issues related to tobacco products. The meeting will be open to the
public. FDA is establishing a docket for public comments related to the
TPSAC meeting.
DATES: The meeting will be held on January 21, 2027, from 9 a.m. to
4:30 p.m. Eastern Time (ET).
ADDRESSES: FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993-
0002. The public will also have the option to participate in person,
and the advisory committee meeting will be heard, viewed, captioned,
and recorded through an online teleconferencing and/or video
conferencing platform.
Answers to commonly asked questions about FDA advisory committee
(AC) meetings, including information regarding special accommodations
due to a disability, visitor parking, and transportation may be
accessed at: https://www.fda.gov/AdvisoryCommittees/default.htm.
FDA is establishing a docket for public comments on this meeting.
The docket number is FDA-2026-N-13368. The docket will close on January
12, 2027. Comments received on or before January 12, 2027, will be
provided to the Committee. The electronic filing system will accept
comments until 11:59 p.m. ET at the end of January 12, 2027. Comments
received by mail/hand delivery/courier (for written/paper submissions)
will be considered timely if they are received on or before that date.
In the event that the meeting is cancelled, FDA will update its website
with information on the rescheduled date and will continue to evaluate
any relevant information, and consider any comments submitted to the
docket, as appropriate.
As required under Section 911 of the FD&C Act, FDA also is
accepting public comments on the Modified Risk Tobacco Product
Application: Renewal Applications for VLN[supreg] King and VLN[supreg]
Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
via Docket No. FDA-2019-N-0994-0230, which is separate from the docket
intended for comments for TPSAC: FDA-2026-N-13368.
For comments to be considered as part of scientific review
for the MRTPA, submit comments to FDA-2019-N-0994-0230. Comments in
this docket will not be referred to the Committee.
For comments to be considered by the TPSAC as part of the
January 21, 2027, TPSAC meeting discussion, submit comments to FDA-
2026-N-13368 by January 12, 2027, as noted above.
For comments to be considered as part of the scientific
review for the MRTPA and the January 21, 2027, TSPAC meeting
discussion, submit comments to both dockets.
You may submit comments as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2026-N-13368 for ``Tobacco Products Scientific Advisory Committee;
Notice of Meeting; Establishment of a Public Docket; Request for
Comments.'' Received comments, those filed in a timely manner (see
ADDRESSES), will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m. ET, Monday through Friday, 240-402-7500.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be
[[Page 75516]]
made publicly available, submit your comments only as a written/paper
submission. You should submit two copies in total. One copy will
include the information you claim to be confidential with a heading or
cover note that states ``THIS DOCUMENT CONTAINS CONFIDENTIAL
INFORMATION.'' FDA will review this copy, including the claimed
confidential information, in its consideration of comments. The second
copy, which will have the claimed confidential information redacted/
blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management
Staff. If you do not wish your name and contact information be made
publicly available, you can provide this information on the cover sheet
and not in the body of your comments and you must identify the
information as ``confidential.'' Any information marked as
``confidential'' will not be disclosed except in accordance with 21 CFR
10.20 and other applicable disclosure law. For more information about
FDA's posting of comments to public dockets, see 80 FR 56469, September
18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852, 240-402-7500.
FOR FURTHER INFORMATION CONTACT:
Advisors and Consultants Staff, Center for Tobacco
Products, Food and Drug Administration, Document Control Center, 10903
New Hampshire Ave., Bldg. 71, Silver Spring, MD 20993-0002, 1-877-287-
1373,
[email protected], or
FDA Advisory Committee Information Line, 1-800-741-8138
(301-443-0572) in the Washington, DC area).
A notice in the Federal Register about last-minute modifications
that impact a previously announced advisory committee meeting cannot
always be published quickly enough to provide timely notice. Therefore,
you should always check FDA's website at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate
advisory committee meeting link or call the advisory committee
information line to learn about possible modifications before the
meeting.
SUPPLEMENTARY INFORMATION:
Agenda: On January 21, 2027, the Committee will convene to discuss
the renewal of modified risk granted orders issued to 22nd Century
Group Inc., for the following combusted cigarette products:
MR0000159: VLN[supreg] King, and
MR0000160: VLN[supreg] Menthol King.
Discussion generally will focus on whether the statutory standard
for exposure modification orders under Section 911(g)(2) continues to
be met.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its website prior to the meeting, the
background material will be made publicly available on FDA's website at
the time of the advisory committee meeting and after the meeting.
Background material will be available at the location of the advisory
committee meeting and at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee
meeting link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the Committee.
Oral presentations from the public will be scheduled approximately
between 1 p.m. and 2 p.m. ET. Those individuals interested in making
formal oral presentations should notify Advisors and Consultants Staff,
CTP (see FOR FURTHER INFORMATION CONTACT) and submit a brief statement
of the general nature of the evidence or arguments they wish to
present, along with the names, phone numbers, and email addresses of
proposed participants on or before December 28, 2026. Time allotted for
each presentation may be limited. If the number of registrants
requesting to speak is greater than can be reasonably accommodated
during the scheduled open public hearing session, FDA may conduct a
lottery to determine the speakers for the scheduled open public hearing
session.
Persons attending FDA's advisory committee meetings are advised
that FDA is not responsible for providing access to electrical outlets.
For press inquiries, please contact the FDA Newsroom at
www.fda.gov/news-events/fda-newsroom.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Advisors and Consultants Staff, CTP (see FOR FURTHER
INFORMATION CONTACT) at least 7 business days in advance of the
meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our website at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. 1001 et seq.). This meeting notice also serves
as notice that, pursuant to 21 CFR 10.19, the requirements in 21 CFR
14.22(g) relating to the location of advisory committee meetings are
hereby waived to allow for this meeting to take place using an online
meeting platform in conjunction with the physical meeting room (see
location). This waiver is in the interest of allowing greater
transparency and opportunities for public participation, in addition to
convenience for advisory committee members, speakers, and guest
speakers. The conditions for issuance of a waiver under 21 CFR 10.19
are met.
Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2026-23750 Filed 11-20-26; 8:45 am]
BILLING CODE 4164-01-P
공식 발표 ↔ 매체 보도
보도 없음
보도 없음
보도 없음